Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 10/20 | 0.55 |
| ▸ | HINT1 | P49773 | 4/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890617 | 0.91 | TGM2 (0.63) | TGM2NT5EKRASHINT1TAS1R3 | |
| SCHEMBL1892944 | 0.88 | POLB (0.58) | TGM2NT5EKRASTAS1R3TAS1R1 | |
| SCHEMBL1891451 | 0.88 | TGM2 (0.63) | TGM2NT5EKRASHINT1TAS1R3 | |
| SCHEMBL1893133 | 0.87 | P2RY1 (0.59) | NT5ETAS1R3TAS1R1 | |
| SCHEMBL1895367 | 0.83 | P2RY2 (0.50) | — | |
| SCHEMBL1894008 | 0.82 | DNPH1 (0.44) | NT5E | |
| SCHEMBL1893832 | 0.81 | P2RY6 (0.53) | — | |
| SCHEMBL1891833 | 0.81 | TGM2 (0.66) | TGM2NT5EKRASHINT1TAS1R3 | |
| SCHEMBL1894736 | 0.80 | TGM2 (0.87) | TGM2NT5EKRASHINT1TAS1R3 | |
| SCHEMBL1889076 | 0.79 | POLB (0.60) | TGM2NT5EKRASTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242087-B2 | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-08-14 | — | — | US | disclosed |
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112046-A9 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | TGM2 2951/4885NT5E 50/4885KRAS 4739/4885 |
| US-20100093656-A1 | PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | MTAP, POLRMT, PNP | TGM2 2951/4885NT5E 50/4885KRAS 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.